CA3208006A1 - Long acting injectable formulation comprising risperidone and biodegradable polymers - Google Patents

Long acting injectable formulation comprising risperidone and biodegradable polymers Download PDF

Info

Publication number
CA3208006A1
CA3208006A1 CA3208006A CA3208006A CA3208006A1 CA 3208006 A1 CA3208006 A1 CA 3208006A1 CA 3208006 A CA3208006 A CA 3208006A CA 3208006 A CA3208006 A CA 3208006A CA 3208006 A1 CA3208006 A1 CA 3208006A1
Authority
CA
Canada
Prior art keywords
risperidone
formulation
long acting
acting injectable
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3208006A
Other languages
English (en)
French (fr)
Inventor
Avia MERENLENDER WAGNER
Anna ELGART VALITSKY
Eran HARARY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedinCell SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3208006A1 publication Critical patent/CA3208006A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3208006A 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers Pending CA3208006A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163162272P 2021-03-17 2021-03-17
US63/162,272 2021-03-17
IB2021052248 2021-03-17
IBPCT/IB2021/052248 2021-03-17
US202163208860P 2021-06-09 2021-06-09
US63/208,860 2021-06-09
US202163270174P 2021-10-21 2021-10-21
US63/270,174 2021-10-21
PCT/EP2022/057009 WO2022195018A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Publications (1)

Publication Number Publication Date
CA3208006A1 true CA3208006A1 (en) 2022-09-22

Family

ID=81307068

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3208006A Pending CA3208006A1 (en) 2021-03-17 2022-03-17 Long acting injectable formulation comprising risperidone and biodegradable polymers

Country Status (10)

Country Link
US (2) US20240148641A1 (enExample)
EP (1) EP4308077A1 (enExample)
JP (1) JP2024511353A (enExample)
KR (1) KR20230158088A (enExample)
AU (1) AU2022236485A1 (enExample)
BR (1) BR112023018652A2 (enExample)
CA (1) CA3208006A1 (enExample)
IL (1) IL304980A (enExample)
MX (1) MX2023010925A (enExample)
WO (1) WO2022195018A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501805A (ja) * 2023-01-10 2026-01-16 メドインセルル エス．エー． オランザピン組成物及び使用の方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012010195A2 (pt) * 2009-10-30 2016-04-26 Janssen Pharmaceutica Nv regime de dosagem associado a ésteres de paliperidona injetável de longa ação
US10463607B2 (en) * 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
KR101424163B1 (ko) * 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
US9023897B2 (en) * 2010-12-29 2015-05-05 Medincell Biodegradable drug delivery compositions
EP2866837B1 (en) 2012-06-27 2022-12-14 Medincell S.A. Biodegradable drug delivery for hydrophobic compositions
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
CN107213136B (zh) * 2017-06-07 2021-06-01 广州帝奇医药技术有限公司 一种长效缓释药物制剂及其制备方法
WO2020154315A1 (en) * 2019-01-22 2020-07-30 Indivior Uk Limited Methods for treating schizophrenia
MX2022003051A (es) * 2019-09-13 2022-06-14 Medincell S A Formulaciones para la administracion de farmacos.

Also Published As

Publication number Publication date
BR112023018652A2 (pt) 2023-10-03
MX2023010925A (es) 2023-09-27
AU2022236485A1 (en) 2023-08-24
US12329851B2 (en) 2025-06-17
EP4308077A1 (en) 2024-01-24
WO2022195018A1 (en) 2022-09-22
JP2024511353A (ja) 2024-03-13
US20240148641A1 (en) 2024-05-09
KR20230158088A (ko) 2023-11-17
US20240325293A1 (en) 2024-10-03
IL304980A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
Tolcher et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
KR102568894B1 (ko) 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템
US12128132B2 (en) Drug delivery formulations
TWI838700B (zh) 口服紫杉烷組合物及方法
JP7030813B2 (ja) 前立腺癌の処置のためのシロリムスの腫瘍内投与
US12329851B2 (en) Long acting injectable formulation comprising risperidone and biodegradable polymers
JP2023552329A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP2023551009A (ja) 持続放出パリペリドン注射可能製剤に関連する投与レジメン
TW201306837A (zh) 使用ｐｉ３ｋ抑制劑及ｍｅｋ抑制劑用於治療癌症之組成物及方法
Hickey et al. Delivery of long-acting injectable antivirals: best approaches and recent advances
Tyler et al. Challenges in the development of intravenous neurokinin‐1 receptor antagonists: results of a safety and pharmacokinetics dose‐finding, phase 1 study of intravenous fosnetupitant
US12220418B2 (en) Olanzapine compositions and methods of use
CN116997323A (zh) 包含利培酮和可生物降解的聚合物的长效可注射制剂
BR122025009310A2 (pt) Formulações de entrega de fármaco
HK40120254B (en) Olanzapine compositions and methods of use
HK40120254A (en) Olanzapine compositions and methods of use
WO2022032146A1 (en) Methods for inhibiting growth of era positive cancers
Toddywala et al. C57 CELLULAR/MOLECULAR MECHANISMS AND TRANSLATIONAL ASPECTS OF RESPIRATORY INFECTIONS: Formulation And Aerosol Characterization Of Select Aminoglycoside-And Fluoroquinolone-Class Antibiotics In A Proprietary Breath Actuated Nebulizer And In Vivo Pharmacokinetics In A Preclinical Mouse Model

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20260313

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260313

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260313

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260313

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20260316

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260316

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260316

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260402

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260402

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260402